Baltazar Gomez-Mancilla, MD, PhD
Novartis Biomedical Research, Cambridge, Massachusetts; Novartis Pharma AG, Basel, Switzerland; McGill University, Montreal, Québec, Canada
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
